Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Post-ET Myelofibrosis”

117 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 117 results

Early research (Phase 1)Study completedNCT01317875
What this trial is testing

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Who this might be right for
Myelofibrosis
Incyte Corporation 69
Large-scale testing (Phase 3)Study completedNCT00934544
What this trial is testing

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

Who this might be right for
Myelofibrosis
Novartis Pharmaceuticals 219
Testing effectiveness (Phase 2)UnknownNCT01298934
What this trial is testing

LBH589 (Panobinostat) for the Treatment of Myelofibrosis

Who this might be right for
Primary MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePost-Essential Thrombocythemia Related Myelofibrosis
Ronald Hoffman 22
Testing effectiveness (Phase 2)Study completedNCT02515630
What this trial is testing

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera (Post-PV) MyelofibrosisPostessential Thrombocythemia (Post-ET) Myelofibrosis
Sierra Oncology LLC - a GSK company 41
Testing effectiveness (Phase 2)Looking for participantsNCT05280509
What this trial is testing

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost-PV MF+1 more
Telios Pharma, Inc. 70
Early research (Phase 1)Looking for participantsNCT05279001
What this trial is testing

A Safety and Tolerability Study of Jaktinib

Who this might be right for
Myelofibrosis
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT03441113
What this trial is testing

Extended Access of Momelotinib in Adults With Myelofibrosis

Who this might be right for
NeoplasmsPost-polycythemia Vera Myelofibrosis (Post-PV MF)Primary Myelofibrosis (PMF)+1 more
GlaxoSmithKline 237
Testing effectiveness (Phase 2)Ended earlyNCT03627403
What this trial is testing

Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

Who this might be right for
Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera Myelofibrosis
University of Utah 17
Early research (Phase 1)Study completedNCT00631462
What this trial is testing

A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis

Who this might be right for
Myelofibrosis
TargeGen 59
Testing effectiveness (Phase 2)Study completedNCT04217993
What this trial is testing

Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis(Post-PV MF)Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 51
Early research (Phase 1)Active Not RecruitingNCT04279847
What this trial is testing

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Who this might be right for
MyelofibrosisMyelodysplastic SyndromeMyelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome+4 more
Incyte Corporation 140
Not applicableLooking for participantsNCT06073847
What this trial is testing

A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Bristol-Myers Squibb 137
Early research (Phase 1)Ended earlyNCT03373877
What this trial is testing

Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost-polycythemia Vera Myelofibrosis+1 more
Samus Therapeutics, Inc. 4
Testing effectiveness (Phase 2)Study completedNCT00935987
What this trial is testing

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
Sierra Oncology LLC - a GSK company 166
Large-scale testing (Phase 3)UnknownNCT03662126
What this trial is testing

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Who this might be right for
Primary Myelofibrosis (PMF)Post-Polycythemia Vera MF (Post-PV-MF)Post-Essential Thrombocythemia MF (Post-ET-MF)
Kartos Therapeutics, Inc. 385
Testing effectiveness (Phase 2)Study completedNCT01633372
What this trial is testing

An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis

Who this might be right for
MPN (Myeloproliferative Neoplasms)
Incyte Corporation 87
Early research (Phase 1)WithdrawnNCT02871323
What this trial is testing

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Who this might be right for
Polycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrimary Myelofibrosis
Northwestern University
Large-scale testing (Phase 3)Study completedNCT02101268
What this trial is testing

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera (Post-PV)Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Sierra Oncology LLC - a GSK company 156
Testing effectiveness (Phase 2)Active Not RecruitingNCT04455841
What this trial is testing

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

Who this might be right for
AnemiaPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera Myelofibrosis
Incyte Corporation 84
Testing effectiveness (Phase 2)Study completedNCT03136185
What this trial is testing

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Who this might be right for
MyelofibrosisPost-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)+1 more
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) 90
Load More Results